BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17075223)

  • 1. Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias.
    Mayo MM; Johns GS
    Contrib Nephrol; 2007; 153():44-65. PubMed ID: 17075223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic criteria of multiple myeloma.
    Kyle RA
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):347-58. PubMed ID: 1582977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Primary amyloidosis and thrombophlebitis as complications of Bence-Jones plasmacytoma (lambda type)].
    Baier J; Neumann H; Grossmann R; Ricken D
    Med Klin (Munich); 1991 Jan; 86(1):53-7. PubMed ID: 1901936
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical aspects of monoclonal gammopathies in diseases of the lympho-plasmacytic cell system].
    Westerhausen M
    Acta Med Austriaca; 1982; 9(4):143-9. PubMed ID: 6814157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical aspects of multiple myeloma and related disorders including amyloidosis.
    Kyle RA
    Pathol Biol (Paris); 1999 Feb; 47(2):148-57. PubMed ID: 10192881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [IL-6, p53 and proto-oncogene c-myc play different roles as biological markers of plasma cell dyscrasias].
    Alvino S; Marcucci M; Canzoniere D; Mosiello A; Del Monte G; Venturo I; Rinaldi M; Gandolfo GM; Lopez M; Greco C
    Clin Ter; 1999; 150(3):197-202. PubMed ID: 10528431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum test for assessment of patients with Bence Jones myeloma.
    Bradwell AR; Carr-Smith HD; Mead GP; Harvey TC; Drayson MT
    Lancet; 2003 Feb; 361(9356):489-91. PubMed ID: 12583950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Light chain or monoclonal immunoglobulin deposition disease: physiopathogenic concepts].
    Preud'homme JL; Mihaesco E; Guglielmi P; Morel-Maroger L; Ganeval D; Danon F; Brouet JC; Mihaesco C; Seligmann M
    Nouv Presse Med; 1982 Nov; 11(44):3259-63. PubMed ID: 6818521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma.
    Iványi B
    Arch Pathol Lab Med; 1990 Sep; 114(9):986-7. PubMed ID: 2117910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma cell dyscrasia. Analysis of 423 patients.
    Pick AI; Shoenfeld Y; Frohlichmann R; Weiss H; Vana D; Schreibman S
    JAMA; 1979 May; 241(21):2275-8. PubMed ID: 108408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyneuropathies associated with plasma cell dyscrasias.
    Kelly JJ
    Semin Neurol; 1987 Mar; 7(1):30-9. PubMed ID: 3332445
    [No Abstract]   [Full Text] [Related]  

  • 12. The search for meaning in monoclonal protein. Is it multiple myeloma or monoclonal gammopathy of undetermined significance?
    Brigden ML
    Postgrad Med; 1999 Aug; 106(2):135-42; quiz 185. PubMed ID: 10456045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of Bence Jones proteins by immunonephelometry.
    Levinson SS
    Ann Clin Lab Sci; 1992; 22(2):100-9. PubMed ID: 1562164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma cell dyscrasias: current status.
    Kyle RA; Greipp PA
    Crit Rev Oncol Hematol; 1988; 8(2):93-152. PubMed ID: 3046767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benign and malignant monoclonal gammopathies.
    Carney DN; Bunn PA
    Prim Care; 1980 Sep; 7(3):369-94. PubMed ID: 6777792
    [No Abstract]   [Full Text] [Related]  

  • 16. The monoclonal gammopathies.
    Kyle RA
    Clin Chem; 1994 Nov; 40(11 Pt 2):2154-61. PubMed ID: 7955402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrotoxic potential of Bence Jones proteins.
    Solomon A; Weiss DT; Kattine AA
    N Engl J Med; 1991 Jun; 324(26):1845-51. PubMed ID: 1904132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical spectrum of light chain myeloma. A study of 35 patients with special reference to the occurrence of amyloidosis.
    Stone MJ; Frendel EP
    Am J Med; 1975 May; 58(5):601-19. PubMed ID: 1130419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
    Bataille R; Jourdan M; Zhang XG; Klein B
    J Clin Invest; 1989 Dec; 84(6):2008-11. PubMed ID: 2592570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin synthesis in primary and myeloma amyloidosis.
    Preud'homme JL; Ganeval D; Grünfeld JP; Striker L; Brouet JC
    Clin Exp Immunol; 1988 Sep; 73(3):389-94. PubMed ID: 3145161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.